November 30, 2018
Paul Laikind is the CEO of ViaCyte, a San Diego company flying high with a recent $80 million Series D round. Photo courtesy of ViaCyte
Stories this photo appears in:
ViaCyte recently hauled in an $80 million Series D round to advance therapies that the company called a potential “functional cure” for Type 1 diabetes patients.